nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoteridol—Cyanosis—Teniposide—lymphatic system cancer	0.0307	0.0307	CcSEcCtD
Gadoteridol—Abdominal cramps—Vincristine—lymphatic system cancer	0.0173	0.0173	CcSEcCtD
Gadoteridol—Stupor—Carmustine—lymphatic system cancer	0.0164	0.0164	CcSEcCtD
Gadoteridol—Injection site pain—Carmustine—lymphatic system cancer	0.015	0.015	CcSEcCtD
Gadoteridol—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0138	0.0138	CcSEcCtD
Gadoteridol—Wheezing—Bleomycin—lymphatic system cancer	0.0136	0.0136	CcSEcCtD
Gadoteridol—Injection site reaction—Carmustine—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Gadoteridol—Dysphagia—Fludarabine—lymphatic system cancer	0.012	0.012	CcSEcCtD
Gadoteridol—Neck stiffness—Methotrexate—lymphatic system cancer	0.0119	0.0119	CcSEcCtD
Gadoteridol—Urinary incontinence—Carmustine—lymphatic system cancer	0.0118	0.0118	CcSEcCtD
Gadoteridol—Depressed level of consciousness—Carmustine—lymphatic system cancer	0.0118	0.0118	CcSEcCtD
Gadoteridol—Sweating—Teniposide—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Gadoteridol—Nuchal rigidity—Methotrexate—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Gadoteridol—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Gadoteridol—Flushing—Teniposide—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Gadoteridol—Face oedema—Carmustine—lymphatic system cancer	0.00857	0.00857	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00852	0.00852	CcSEcCtD
Gadoteridol—Hypertension—Teniposide—lymphatic system cancer	0.0082	0.0082	CcSEcCtD
Gadoteridol—Chest pain—Teniposide—lymphatic system cancer	0.00809	0.00809	CcSEcCtD
Gadoteridol—Cardiac arrest—Vincristine—lymphatic system cancer	0.00805	0.00805	CcSEcCtD
Gadoteridol—Cyanosis—Methotrexate—lymphatic system cancer	0.008	0.008	CcSEcCtD
Gadoteridol—Oedema—Teniposide—lymphatic system cancer	0.00775	0.00775	CcSEcCtD
Gadoteridol—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00775	0.00775	CcSEcCtD
Gadoteridol—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00775	0.00775	CcSEcCtD
Gadoteridol—Dysphagia—Carmustine—lymphatic system cancer	0.00767	0.00767	CcSEcCtD
Gadoteridol—Stupor—Methotrexate—lymphatic system cancer	0.00758	0.00758	CcSEcCtD
Gadoteridol—Malaise—Fludarabine—lymphatic system cancer	0.00753	0.00753	CcSEcCtD
Gadoteridol—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00749	0.00749	CcSEcCtD
Gadoteridol—Pruritus—Mechlorethamine—lymphatic system cancer	0.00744	0.00744	CcSEcCtD
Gadoteridol—Cough—Fludarabine—lymphatic system cancer	0.00729	0.00729	CcSEcCtD
Gadoteridol—Hypotension—Teniposide—lymphatic system cancer	0.00724	0.00724	CcSEcCtD
Gadoteridol—Convulsion—Fludarabine—lymphatic system cancer	0.00723	0.00723	CcSEcCtD
Gadoteridol—Gingivitis—Methotrexate—lymphatic system cancer	0.00721	0.00721	CcSEcCtD
Gadoteridol—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00719	0.00719	CcSEcCtD
Gadoteridol—Discomfort—Fludarabine—lymphatic system cancer	0.00702	0.00702	CcSEcCtD
Gadoteridol—Dyspnoea—Teniposide—lymphatic system cancer	0.00691	0.00691	CcSEcCtD
Gadoteridol—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00681	0.00681	CcSEcCtD
Gadoteridol—Oedema—Fludarabine—lymphatic system cancer	0.00681	0.00681	CcSEcCtD
Gadoteridol—Vomiting—Mechlorethamine—lymphatic system cancer	0.00669	0.00669	CcSEcCtD
Gadoteridol—Apnoea—Methotrexate—lymphatic system cancer	0.00668	0.00668	CcSEcCtD
Gadoteridol—Rash—Mechlorethamine—lymphatic system cancer	0.00663	0.00663	CcSEcCtD
Gadoteridol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00662	0.00662	CcSEcCtD
Gadoteridol—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00659	0.00659	CcSEcCtD
Gadoteridol—Flushing—Bleomycin—lymphatic system cancer	0.00653	0.00653	CcSEcCtD
Gadoteridol—Feeling abnormal—Teniposide—lymphatic system cancer	0.00639	0.00639	CcSEcCtD
Gadoteridol—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.00631	0.00631	CcSEcCtD
Gadoteridol—Sweating—Vincristine—lymphatic system cancer	0.00626	0.00626	CcSEcCtD
Gadoteridol—Nausea—Mechlorethamine—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Gadoteridol—Urticaria—Teniposide—lymphatic system cancer	0.00616	0.00616	CcSEcCtD
Gadoteridol—Abdominal pain—Teniposide—lymphatic system cancer	0.00613	0.00613	CcSEcCtD
Gadoteridol—Body temperature increased—Teniposide—lymphatic system cancer	0.00613	0.00613	CcSEcCtD
Gadoteridol—Erythema—Bleomycin—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Gadoteridol—Paraesthesia—Fludarabine—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Gadoteridol—Sweating—Mitoxantrone—lymphatic system cancer	0.00609	0.00609	CcSEcCtD
Gadoteridol—Dyspnoea—Fludarabine—lymphatic system cancer	0.00607	0.00607	CcSEcCtD
Gadoteridol—Pain—Fludarabine—lymphatic system cancer	0.00583	0.00583	CcSEcCtD
Gadoteridol—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00581	0.00581	CcSEcCtD
Gadoteridol—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00572	0.00572	CcSEcCtD
Gadoteridol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00571	0.00571	CcSEcCtD
Gadoteridol—Flushing—Carmustine—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Gadoteridol—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Gadoteridol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Gadoteridol—Malaise—Bleomycin—lymphatic system cancer	0.00552	0.00552	CcSEcCtD
Gadoteridol—Pruritus—Teniposide—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Gadoteridol—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00547	0.00547	CcSEcCtD
Gadoteridol—Body temperature increased—Fludarabine—lymphatic system cancer	0.00539	0.00539	CcSEcCtD
Gadoteridol—Erythema—Carmustine—lymphatic system cancer	0.00534	0.00534	CcSEcCtD
Gadoteridol—Cough—Bleomycin—lymphatic system cancer	0.00534	0.00534	CcSEcCtD
Gadoteridol—Diarrhoea—Teniposide—lymphatic system cancer	0.0053	0.0053	CcSEcCtD
Gadoteridol—Chest pain—Bleomycin—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Gadoteridol—Discomfort—Bleomycin—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Gadoteridol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Gadoteridol—Tremor—Carmustine—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Gadoteridol—Oedema—Bleomycin—lymphatic system cancer	0.005	0.005	CcSEcCtD
Gadoteridol—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.005	0.005	CcSEcCtD
Gadoteridol—Erythema—Mitoxantrone—lymphatic system cancer	0.00497	0.00497	CcSEcCtD
Gadoteridol—Vomiting—Teniposide—lymphatic system cancer	0.00493	0.00493	CcSEcCtD
Gadoteridol—Rash—Teniposide—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Gadoteridol—Dermatitis—Teniposide—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Gadoteridol—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Gadoteridol—Headache—Teniposide—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Gadoteridol—Pruritus—Fludarabine—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Gadoteridol—Hypotension—Bleomycin—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Gadoteridol—Diarrhoea—Fludarabine—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Gadoteridol—Convulsion—Carmustine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Gadoteridol—Hypertension—Carmustine—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Gadoteridol—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Gadoteridol—Nausea—Teniposide—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Gadoteridol—Chest pain—Carmustine—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Gadoteridol—Anxiety—Carmustine—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Gadoteridol—Paraesthesia—Bleomycin—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Gadoteridol—Malaise—Mitoxantrone—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Gadoteridol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Gadoteridol—Convulsion—Vincristine—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Gadoteridol—Hypertension—Vincristine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Gadoteridol—Oedema—Carmustine—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Gadoteridol—Cough—Mitoxantrone—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Gadoteridol—Vomiting—Fludarabine—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Gadoteridol—Convulsion—Mitoxantrone—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Gadoteridol—Rash—Fludarabine—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Gadoteridol—Dermatitis—Fludarabine—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Gadoteridol—Hypertension—Mitoxantrone—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Gadoteridol—Pain—Bleomycin—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Gadoteridol—Headache—Fludarabine—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Gadoteridol—Chest pain—Mitoxantrone—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Gadoteridol—Anxiety—Mitoxantrone—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Gadoteridol—Discomfort—Mitoxantrone—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Gadoteridol—Oedema—Vincristine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Gadoteridol—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Gadoteridol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Gadoteridol—Hypotension—Carmustine—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Gadoteridol—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Gadoteridol—Oedema—Mitoxantrone—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Gadoteridol—Nausea—Fludarabine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Gadoteridol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Gadoteridol—Shock—Mitoxantrone—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Gadoteridol—Urticaria—Bleomycin—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Gadoteridol—Body temperature increased—Bleomycin—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Gadoteridol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Gadoteridol—Paraesthesia—Carmustine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Gadoteridol—Hypotension—Vincristine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Gadoteridol—Dyspnoea—Carmustine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Gadoteridol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Gadoteridol—Paraesthesia—Vincristine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Gadoteridol—Pain—Carmustine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Gadoteridol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Gadoteridol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Gadoteridol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Gadoteridol—Feeling abnormal—Carmustine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Gadoteridol—Pain—Vincristine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Gadoteridol—Pruritus—Bleomycin—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Gadoteridol—Pain—Mitoxantrone—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Gadoteridol—Abdominal pain—Carmustine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Gadoteridol—Body temperature increased—Carmustine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Gadoteridol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Gadoteridol—Abdominal pain—Vincristine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Gadoteridol—Body temperature increased—Vincristine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Gadoteridol—Urticaria—Mitoxantrone—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Gadoteridol—Hypersensitivity—Carmustine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Gadoteridol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Gadoteridol—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Gadoteridol—Vomiting—Bleomycin—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Gadoteridol—Rash—Bleomycin—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Gadoteridol—Dermatitis—Bleomycin—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Gadoteridol—Hypersensitivity—Vincristine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Gadoteridol—Sweating—Methotrexate—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Gadoteridol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Gadoteridol—Diarrhoea—Carmustine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Gadoteridol—Nausea—Bleomycin—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Gadoteridol—Dizziness—Carmustine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Gadoteridol—Diarrhoea—Vincristine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Gadoteridol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Gadoteridol—Vomiting—Carmustine—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Gadoteridol—Dizziness—Vincristine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Gadoteridol—Rash—Carmustine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Gadoteridol—Dermatitis—Carmustine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Gadoteridol—Headache—Carmustine—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Gadoteridol—Tinnitus—Methotrexate—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Gadoteridol—Vomiting—Vincristine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Gadoteridol—Rash—Vincristine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Gadoteridol—Dermatitis—Vincristine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Gadoteridol—Headache—Vincristine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Gadoteridol—Nausea—Carmustine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Gadoteridol—Vomiting—Mitoxantrone—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Gadoteridol—Rash—Mitoxantrone—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Gadoteridol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Gadoteridol—Headache—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Gadoteridol—Erythema—Methotrexate—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Gadoteridol—Nausea—Vincristine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Gadoteridol—Dysgeusia—Methotrexate—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Gadoteridol—Nausea—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Gadoteridol—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Gadoteridol—Malaise—Methotrexate—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Gadoteridol—Cough—Methotrexate—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Gadoteridol—Convulsion—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Gadoteridol—Chest pain—Methotrexate—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Gadoteridol—Discomfort—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Gadoteridol—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Gadoteridol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Gadoteridol—Hypotension—Methotrexate—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Gadoteridol—Paraesthesia—Methotrexate—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Gadoteridol—Dyspnoea—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Gadoteridol—Pain—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Gadoteridol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Gadoteridol—Urticaria—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Gadoteridol—Abdominal pain—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Gadoteridol—Body temperature increased—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Gadoteridol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Gadoteridol—Pruritus—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Gadoteridol—Diarrhoea—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Gadoteridol—Dizziness—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Gadoteridol—Vomiting—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Gadoteridol—Rash—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Gadoteridol—Dermatitis—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Gadoteridol—Headache—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Gadoteridol—Nausea—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
